PU-02; PU02
PU-02; PU02 用途与合成方法
|
5-HT 3A Receptor 0.36 μM (IC 50 ) |
5-HT 3 AB 0.73 μM (IC 50 ) |
PU02 (NMMP) (0-200 μM) leads to a steady decrease in cell viability of HepG2 cells (IC
50
=48.585 μM). PU02 (NMMP) shows less toxicity on L02 cells than did 6-MP after 48 h of treatment.
PU02 (NMMP) at 6.25 or 25 μM exhibits inhibitory effects on the viability of the tested cell lines, including SMMC-7721, MDA-MB-231, RKO and HCT-8 cells.
PU02 (NMMP) induces cell cycle arrest at the G2/M phase. PU02 (NMMP) downregulats the expression of cyclin B1/D1 and CDK4 in a time-dependent manner in HepG2 cells,but the expression of cyclin E is not affected.
PU02 (NMMP)-treated cells exhibits a significant increase in caspase-3 cleavage, suggesting enhanced apoptotic activity.
Apoptosis Analysis
| Cell Line: | HepG2 cells. |
| Concentration: | 6.26, 12.5, 25, 50 μM. |
| Incubation Time: | 6, 12, 24, 36 h. |
| Result: | Induced mitochondria-dependent apoptosis. |
PU-02; PU02 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-08-19 | HY-103118 | 5 mg | 700 | ||
| 2024-08-19 | HY-103118 | PU-02; PU02 | 313984-77-9 | 10mM * 1mLin DMSO | 770 |
